Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman Research Institute (HRI), which will be renamed as “CenExel CNS” and “CenExel HRI”,...
News at CenExel
CenExel Acquires iResearch
Salt Lake City, May 3, 2022 /GlobeNewswire/ — CenExel announces the acquisition of iResearch (“CenExel iResearch”), a leading multi-specialty research site business with locations in Decatur, GA and Savannah, GA. CenExel iResearch has deep experience conducting Phase...
CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center
Salt Lake City, January 11, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Rocky Mountain Movement Disorders Center’s clinical research site operations. CenExel Rocky Mountain Clinical Research (“CenExel RMCR”) is a...
CenExel Clinical Research Acquires California Neuroscience Research
Salt Lake City, January 10, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research facility in Los Angeles with two decades of experience in neurological...
Join CenExel at CNS Summit 2021
CenExel Clinical Research Network is excited to announce our presence at the upcoming CNS Summit 2021 in Boston, Massachusetts on November 7-11, 2021. The mission of the CNS Summit is to have a positive impact on the success of clinical development programs as an...
Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, August 12, 2021 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase 2b study of its...